
Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock.
Ascendis Pharma reported positive five-year results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) for adult hypoparathyroidism. The therapy maintained stable calcium levels, kidney and bone health, and quality of life, all...


